What Does the Amyloid PET Scan Show in an Alzheimer’s Evaluation?

Learn what positive and negative amyloid scans mean for diagnosis, treatment eligibility, and next steps.

An amyloid PET scan shows where beta-amyloid plaques sit in the brain and how dense the buildup is. Beta-amyloid plaques are sticky protein clumps tied to Alzheimer's disease, and the scan estimates their density during evaluation for thinking decline. Nebraska Medicine describes the test as an add-on to clinical exams for adults with cognitive impairment. It helps separate Alzheimer's pathology from other possible causes of decline.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

How does the scan capture plaques?

The test uses an injected fluorine-18 tracer that sticks to plaques. A PET camera then maps where the tracer collects across the brain.

The Journal of Nuclear Medicine Technology describes this binding and imaging process in the SNMMI technology update. Three approved tracers share this same plaque-binding method. The Alzheimer's Association clinician summary names florbetapir Amyvid, flutemetamol Vizamyl, and florbetaben Neuraceq for estimating plaque density.

What does a negative result mean?

A negative scan means sparse to no neuritic plaques. The FDA Amyvid approval documents state this pattern is inconsistent with Alzheimer's pathology at imaging time in the FDA Amyvid approval documents.

In practice, a negative result lowers the chance that memory loss comes from Alzheimer's. The care team can then focus more on other medical, neurologic, or mood-related causes.

What does a positive result mean?

A positive scan means moderate to frequent plaques. The Eli Lilly and FDA label statement says this supports Alzheimer's pathology but also appears in other brain disorders and in cognitively normal older adults, so it alone does not diagnose dementia, according to the 2012 FDA label statement.

The reader should treat a positive scan as one piece of evidence. History, exam findings, cognitive testing, and other scans still decide what the symptoms mean.

Who fits the test best?

The SNMMI and Alzheimer's Association taskforce reserves the scan for selected cases. It points to persistent unexplained memory problems with objective impairment, atypical possible Alzheimer's, or progressive dementia starting before age 65.

The same taskforce calls other uses inappropriate. Examples include no symptoms, typical late-onset memory loss, staging severity, or testing based only on family history or ApoE status.

  • Persistent memory problems with measured impairment and unclear cause
  • Atypical clinical features where Alzheimer's remains possible
  • Progressive early-onset dementia before age 65

How do results guide next steps?

A positive result helps determine eligibility for anti-amyloid therapies. Pharmaceutical Executive reports that expanded Amyvid labeling also supports visual reads and quantitative plaque assessment, including tracking plaque change during therapy evaluation. Coverage is local rather than automatic.

CMS ended national coverage-with-evidence-development on Oct. 13, 2023 and left decisions to regional Medicare contractors, as explained in the CMS decision memo. Ask the memory clinic what the regional contractor requires before scheduling.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.